Compositions comprising Sanguisorba officinalis root extract and uses thereof. The present invention relates to a root extract of Sanguisorba officinalis and use thereof as an active ingredient for skin care and/or scalp care.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
The present invention concerns a root extract from plants of the Morus genus (in particular Morus albaet, Morus nigra) that is rich in prenylated polyphenols chosen from: moracenin A, moracenin B, kuwanon C, wittiorumin F and mulberrofuran T, a method for preparing such an extract and a cosmetic composition and a pharmaceutical or nutraceutical composition, said compositions comprising, as the active ingredient, at least one root extract from plants of the Morus genus according to the invention.
Disclosed are glycol esters of dicaffeoylquinic acids, in particular dipropylene glycol esters of dicaffeoylquinic acids (DPG esters of DCQ) and propane-1.3-diol esters of dicaffeoylquinic acids of general formula:
5 are a caffeoyl group, the other two being a hydrogen atom. Also disclosed is a plant extract including same, the method for preparing same and a cosmetic composition including the compounds or extracts, intended for preventing or delaying the appearance of skin ageing effects.
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
A61K 36/39 - Convolvulaceae (Morning-glory family), e.g. bindweed
C07C 39/17 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings
C07C 69/757 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
The invention relates to a root extract of Polygonum multiflorum with a THSG concentration and no or very little emodin. The invention also relates to a method for producing such an extract and to a cosmetic composition and a pharmaceutical or nutraceutical composition, said compositions comprising, as the active agent, at least one root extract of Polygonum multiflorum according to the invention.
01 - Chemical and biological materials for industrial, scientific and agricultural use
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
42 - Scientific, technological and industrial services, research and design
Goods & Services
Plant extracts, other than essential oils, used in the
manufacture of cosmetics; chemical substances intended for
use in industry. Plant extracts for cosmetic use; plant-based essential
oils; cosmetics; cosmetic dye. Scientific research in plant biology; research and
development in cosmetology; biochemical research and
development; chemistry services; chemical research;
research and development in the field of chemistry;
extracting the active ingredients of plants for the benefit
of others.
7.
PREPARATION OF A ROOT EXTRACT OF FILIPENDULA ULMARIA AND COSMETIC USES THEREOF
The invention relates to a method for preparing a root extract of Filipendula ulmaria, to a root extract directly obtained by such a method, and to a cosmetic composition comprising, as an active agent, at least one root extract obtained by a method according to the invention. The cosmetic composition according to the invention can be used in energising or refreshing skin care methods.
01 - Chemical and biological materials for industrial, scientific and agricultural use
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
42 - Scientific, technological and industrial services, research and design
Goods & Services
Plant extracts, other than essential oils, used in the manufacture of cosmetics; chemical substances intended for use in industry, namely chemical additives for use in the manufacture of cosmetics Plant extracts sold as components of cosmetics; plant-based essential oils; cosmetics; cosmetic hair dye Scientific research in plant biology; research and development in cosmetology; biochemical research and development; chemistry consultation services; chemical research; research and development in the field of chemistry; research for the benefit of others in the field of extracting the active ingredients of plants
9.
EXTRACTS OF PLANTS FROM THE TAGETES GENUS AND USES OF SAME
The present invention concerns an extract of plants from the Tagetes genus enriched with leontopodic acid B, a method for preparing such an extract and a cosmetic composition and a nutraceutical composition and a pharmaceutical composition, said compositions comprising, as the active agent, at least one extract of plants from the Tagetes genus according to the invention. The invention also concerns the use of an extract according to the invention, in particular as a drug for preventing and/or treating a neurodegenerative disease, in particular Alzheimer's disease; and also a cosmetic composition comprising an extract according to the invention.
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
10.
SUBSTITUTED HEXARIC ACID DERIVATIVES AND USES THEREOF
The invention relates to polysubstituted hexaric acids and the ester derivatives thereof, of general formula (I), wherein R1 and R2 are a hydrogen atom or an optionally substituted C1-C18 alkyl group, and Q1, Q2, Q3 and Q4 are a caffeoyl group, a CH3-CH(OH)-CH2-CO- group or a hydrogen atom, provided that at least one of these radicals is a caffeoyl group, for use in preventing and/or treating a neurodegenerative disease, in particular Alzheimer's disease. The invention also relates to compounds of formula (I) as such, such compounds to be used as a medicament, in particular for preventing and/or treating a neurodegenerative disease such as Alzheimer's disease, and a pharmaceutical or nutraceutical composition comprising at least one of these compounds.
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/25 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
11.
POLYSUBSTITUTED QUINIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
The present invention relates to polysubstituted quinic acid derivatives (abbreviated to "PSQs") of general formula (IA): in which R represents a linear or branched, cyclic or branched cyclic, saturated or unsaturated C2-Cp alkyl group, said group being able to be substituted or unsubstituted, p being a natural integer between 3 and 18, and Q1, Q3, Q4 and Q5 each representing, independently of one another, a hydrogen atom or a group selected from caffeoyl, maloyl, caffeoylmaloyl and maloylcaffeoyl groups, with the proviso that at least one of these radicals is not a hydrogen atom, the stereoisomers thereof and the pharmaceutically or nutraceutically acceptable salts thereof, for the prevention and/or the treatment of a neurodegenerative disease, especially Alzheimer's disease. Another subject of the invention is compounds of formula (IA) per se, a process for preparing such compounds, compounds according to the invention intended to be used as medicament, especially for the prevention and/or treatment of a neurodegenerative disease, in particular Alzheimer's disease, and a pharmaceutical composition comprising at least one compound according to the invention.
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
C07C 69/757 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
12.
INSTALLATION AND METHOD FOR THE AEROPONIC/HYDROPONIC PRODUCTION OF PLANTS
An installation for the aeroponic/hydroponic production of plants (P) comprises at least a table (1), trays (2) able to move on the table (1) and intended to support the plants (P) so as to transfer the plants (P), the installation being characterized in that it comprises a dipping station (14) comprising a lift for lowering and raising at least one tray (2) between a raised position and a lowered position so as to dip the roots (PR) in a dipping bath (140) containing a liquid in the lowered position for a predetermined length of time.
The invention relates to a method for determining the affinity between ligands and a target. According to said method, a mixture is prepared with a target and a sample formed from a mixture of ligands in controlled proportions so that the ligands having an affinity with the target bind thereto; the mixture is filtered so as to keep only the target-ligand complexes; the separation of the target-ligand complexes is provoked; the ligands and the targets are separated; the ligands are recovered by filtration in a treated solution and said treated solution is analysed to identify the presence of the ligands; the treated solution being analysed by relatively quantifying the ligands, the ligands present in a larger quantity having the greatest affinity with the target.
G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
The invention relates to glycol esters of dicaffeoylquinic acids, in particular dipropylene glycol esters of dicaffeoylquinic acids (DPG esters of DCQ) and propane-1,3-diol esters of dicaffeoylquinic acids of general formula (I): wherein R1 is a dipropylene glycol radical or a propane-1,3-diol radical, and any two of the radicals R2, R3, R4 and R5 are a caffeoyl group, the other two being a hydrogen atom. The present invention also relates to a plant extract including same, the method for preparing same and a cosmetic composition including the compounds or extracts according to the invention, intended for preventing or delaying the appearance of skin ageing effects.
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
A61K 36/39 - Convolvulaceae (Morning-glory family), e.g. bindweed
C07C 39/17 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings
15.
ENZYMES FOR THE BIOCONVERSION OF CHLOROGENIC ACID INTO AT LEAST ONE DI-, TRI- OR TETRA-CAFFEOYLQUINIC ACID
The present invention concerns proteins capable of converting chlorogenic acid into at least one di-, tri- or tetra-caffeoylquinic acid, comprising a sequence of amino acids chosen from SEQ ID NO:33 and SEQ ID NO:8 to SEQ ID NO:18, sequences homologous to these specific sequences, or fragments of such sequences that retain the activity of converting chlorogenic acid into at least one di-, tri- or tetra-caffeoylquinic acid. It also concerns isolated nucleic acid molecules coding for such proteins, and expression vectors of these sequences, host cells and transgenic plants. It further concerns the use of these proteins, expression vectors, host cells or transgenic plants to convert chlorogenic acid into at least one di-, tri- or tetra-caffeoylquinic acid, and various methods of producing at least one di-, tri- or tetra-caffeoylquinic acid from chlorogenic acid.
